← FDA DRUG APPROVALS

FDA ANDA · ANDA210077

NYSTATIN AND TRIAMCINOLONE ACETONIDE

Sponsor: STRIDES PHARMA

APPLICATION
ANDA210077
TYPE
ANDA
ORIGINAL APPROVAL
2018-01-29
LATEST ACTION
2018-01-29
ROUTE
TOPICAL
DOSAGE FORM
OINTMENT
MARKETING STATUS
Discontinued

Products

NYSTATIN AND TRIAMCINOLONE ACETONIDEDiscontinued
NYSTATIN 100,000 UNITS/GM, TRIAMCINOLONE ACETONIDE 0.1% · OINTMENT · TOPICAL

Approval history

2018-01-29UNKNOWN · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →